Study #2025-0988
The CAROLYN trial: Lisocabtagene Maraleucel as first-line therapy for primary central nervous system lymphoma (PCNSL) in transplant-ineligible patients
MD Anderson Study Status
Enrolling
Treatment Agent
Rituximab, Methotrexate, Procarbazine, Temozolomide, Liso-cel, Fludarabine, Cyclophosphamide, Calcium folinate
Description
The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lymphoma
Study phase:
Phase II
Physician name:
Ayushi Chauhan
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.